Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively wit...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ribero, David (author)
مؤلفون آخرون:	Wang, Huamin (author), Donadon, Matteo (author), Zorzi, Daria (author), Thomas, Melanie B. (author), Eng, Cathy (author), Chang, David Z. (author), Curley, Steven A. (author), Abdalla, Eddie K. (author), Ellis, Lee (author), Vauthey, Nicolas (author)
التنسيق:	article
منشور في:	2007
الوصول للمادة أونلاين:	http://hdl.handle.net/10725/2578 http://dx.doi.org/10.1002/cncr.23099 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

مواد مشابهة